Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, Lentivirus Modified CD4 T Cells for HIV Functional Cure

Overview
Describes a manufacturing process for HIV Gag-specific CD4 T cells modified with AGT103 lentivirus. The process was improved by combining CliniMACS Prodigy with static culture in G-Rex® 500M-CS vessels, significantly increasing cell expansion and yield compared to the automated system alone.
What this paper found
A clinical-scale process was developed to make autologous CD4 T cells enriched for HIV Gag specificity and protected from HIV by the lentiviral vector AGT103, which targets CCR5 plus HIV Tat and Vif. In small-scale work, Gag peptide stimulation followed by depletion of CD8, CD56, CD19 and γδ cells raised Gag-specific CD4 T cells from 0.04% to 9.91%, with 4,607-fold expansion, and effector memory cells formed the main subset (80.28%). AGT103 cut CCR5 on JC53 cells by more than 98%. Running the process on a CliniMACS Prodigy with expansion in a G-Rex® 500M-CS vessel gave an average of 15.13% Gag-specific CD4 cells and 7 × 10^8 Gag-specific cells per product in large-scale runs with seven additional donors, six responding consistently.
Note: One of the seven additional donors in the large-scale runs responded poorly to Gag peptide stimulation.
The protocol for clinical-scale manufacturing of HIV-specific and HIV-resistant CD4 T cells is an important step toward effective immunotherapy for HIV disease. — Haishan Li, Tyler Lahusen, Lingzhi Xiao, Nidal Muvarak, Jana Blazkova, Tae-Wook Chun, C. David Pauza, Molecular Therapy - Methods & Clinical Development
Study details
- Authors
- Haishan Li, Tyler Lahusen, Lingzhi Xiao, Nidal Muvarak, Jana Blazkova, Tae-Wook Chun, C. David Pauza
- Institution
- American Gene Technologies International, Rockville, MD, USA · Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA
- Journal
- Molecular Therapy - Methods & Clinical Development
- Year
- 2020
- G-Rex® model(s)
- G-Rex®500M-CS
- Cell type(s)
- VST Cells
- Application area
- Infectious disease
- Study phase
- Preclinical
How G-Rex® was used
PBMC isolation, activation, CD8/CD56/CD19 depletion and AGT103 transduction were run on a CliniMACS Prodigy, and on day 5 the cells were distributed into a G-Rex® 500M-CS vessel for static expansion at a seeding density equivalent to 1 × 10^6 cells/cm2. IL-7 and IL-15 stayed stable from day 5 to day 14, so no further feeding or cell manipulation was needed before harvest on day 12. Adding the G-Rex® step improved total-cell expansion and Gag-specific CD4 T cell percentages compared with Prodigy-only culture. Across seven additional donors, final products averaged 15.13% Gag-specific CD4 cells and a yield of 7 × 10^8.
Explore related
Full citation
Li H, Lahusen T, Xiao L, et al. Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure. Mol Ther Methods Clin Dev. 2020;17:1048-1060.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.